Anti-tumor necrosis factor-α therapies attenuate adaptive arteriogenesis in the rabbit

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 289, Issue 4 58-4, 2005, Pages

  Grundmann, Sebastian ^a,b,c   Hoefer, Imo ^a,c   Ulusans, Susann ^a   Van Royen, Niels ^b   Schirmer, Stephan H ^a   Ozaki, C Keith ^d   Bode, Christoph ^a   Piek, Jan J ^b   Buschmann, Ivo ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Collateral circulation; Growth factors

Indexed keywords

CD11B ANTIGEN; ETANERCEPT; GROWTH FACTOR; INFLIXIMAB; MICROSPHERE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADAPTATION; ADAPTIVE ANGIOGENESIS; ANGIOGENESIS; ANGIOGRAPHY; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTERY OCCLUSION; ARTICLE; BLOOD VESSEL DIAMETER; CELL INFILTRATION; CELL PROLIFERATION; CHRONIC INFLAMMATION; COLLATERAL CIRCULATION; CONDUCTANCE; CONTROLLED STUDY; CROHN DISEASE; FEMORAL ARTERY; FLUORESCENCE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RHEUMATOID ARTHRITIS; VASCULAR SMOOTH MUSCLE;

ANGIOGRAPHY; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11B; ANTIRHEUMATIC AGENTS; APOPTOSIS; ARTERIAL OCCLUSIVE DISEASES; FEMORAL ARTERY; FLOW CYTOMETRY; IMMUNOGLOBULIN G; LIGATION; MONOCYTES; NEOVASCULARIZATION, PHYSIOLOGIC; RABBITS; RECEPTORS, TUMOR NECROSIS FACTOR; REGIONAL BLOOD FLOW; TUMOR NECROSIS FACTOR-ALPHA;

EID: 25444526339     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00959.2004     Document Type: Article

References (42)

1. Arras M, Ito WD, Scholz D, Winkler B, Schaper J, and Schaper W. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest 101: 40-50, 1998.
2. Baeten D, Kruithof E, Van den Bosch F, Demetter P, Van Damme N, Cuvelier C, De Vos M, Mielants II, Veys EM, and De Keyser F. Immunomodulatory effects of anti-tumor necrosis factor-α therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 44: 186-195, 2001.
3. Bozkurt B, Kribbs SB, Clubb FJ Jr, Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, and Mann DL. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation 97: 1382-1391, 1998.
4. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, Walker-Smith JA, and MacDonald TT. Tumor necrosis factor-α-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106: 1455-1466, 1994.
5. Bryant D, Becker L, Richardson J, Shelton J, Franco F, Peshock R, Thompson M, and Giroir B. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-α. Circulation 97: 1375-1381, 1998.
6. Buschmann I, Heil M, Jost M, and Schaper W. Influence of inflammatory cytokines on arteriogenesis. Microcirculation 10: 371-379, 2003.
7. Buschmann IR, Hoefer IE, van Royen N, Katzer E, Braun-Dulleaus R, Heil M, Kostin S, Bode C, and Schaper W. GM-CSF: a strong arteriogenic factor acting by amplification of monocyte function. Atherosclerosis 159: 343-356, 2001.
8. Cai W, Vosschulte R, Afsah-Hedjri A, Koltai S, Kocsis E, Scholz D, Kostin S, Schaper W, and Schaper J. Altered balance between extracellular proteolysis and antiproteolysis is associated with adaptive coronary arteriogenesis. J Mol Cell Cardiol 32: 997-1011, 2000.
9. Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, Leboulch P, and Cao Y. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 9: 604-613, 2003.
10. Chung ES, Packer M, Lo KH, Fasanmade AA, and Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107: 3133-3140, 2003.
11. Deindl E, Buschmann I, Hoefer IE, Podzuweit T, Boengler K, Vogel S, van Royen N, Fernandez B, and Schaper W. Role of ischemia and of hypoxia-inducible genes in arteriogenesis after femoral artery occlusion in the rabbit. Circ Res 89: 779-786, 2001.
12. Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, and Mann DL. Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 99: 3224-3226, 1999.
13. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, and Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103: 2055-2059, 2001.
14. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor-α (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105-1110, 1994.
15. Fulton WFM. The Coronary Arteries. Springfield, IL: Thomas, 1965.
16. Heil M, Clauss M, Suzuki K, Buschmann IR, Willuweit A, Fischer S, and Schaper W. Vascular endothelial growth factor (VEGF) stimulates monocyte migration through endothelial monolayers via increased integrin expression. Eur J Cell Biol 79: 850-857, 2000.
17. Heil M, Ziegelhoeffer T, Pipp F, Kostin S, Martin S, Clauss M, and Schaper W. Blood monocyte concentration is critical for enhancement of collateral artery growth. Am J Physiol Heart Circ Physiol 283: H2411-H2419, 2002.
18. Hoefer I, van Royen N, Buschmann I, Piek J, and Schaper W. Time course of arteriogenesis following femoral artery occlusion in the rabbit. Cardiovasc Res 49: 609-617, 2001.
19. Hoefer IE, van Royen N, Rectenwald JE, Bray EJ, Abouhamze Z, Moldawer LL, Voskuil M, Piek JJ, Buschmann IR, and Ozaki CK. Direct evidence for tumor necrosis factor-α signaling in arteriogenesis. Circulation 105: 1639-1641, 2002.
20. Hoefer IE, van Royen N, Rectenwald JE, Deindl E, Hua J, Jost M, Grundmann S, Voskuil M, Ozaki CK, Piek JJ, and Buschmann IR. Arteriogenesis proceeds via ICAM-1/Mac-1-mediated mechanisms. Circ Res 94: 1179-1185, 2004.
21. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, Bechir M, Spieker LE, Neidhart M, Michel BA, Gay RE, Luscher TF, Gay S, and Ruschitzka F. Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106: 2184-2187, 2002.
22. Ito WD, Arras M, Winkler B, Scholz D, Schaper J, and Schaper W. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ Res 80: 829-837, 1997.
23. Krasinski K, Spyridopoulos I, Kearney M, and Losordo D. In vivo blockade of tumor necrosis factor-α accelerates functional endothelial recovery after balloon angioplasty. Circulation 104: 1754-1756, 2001.
24. Levine B, Kalman J, Mayer L, Fillit HM, and Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323: 236-241, 1990.
25. Longland CJ. The collateral circulation of the limb. Ann R Coll Surg Engl 13: 161-164, 1953.
26. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, and Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121: 1145-1157, 2001.
27. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, and Fleming T. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109: 1594-1602, 2004.
28. Nilsen EM, Johansen FE, Jahnsen FL, Lundin KE, Scholz T, Brandtzaeg P, and Haraldsen G. Cytokine profiles of cultured microvascular endothelial cells from the human intestine. Gut 42: 635-642, 1998.
29. Packer M. Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure? Circulation 92: 1379-1382, 1995.
30. Peppel K, Zhang L, Orman ES, Hagen PO, Amalfitano A, Brian L, and Freedman NJ. Activation of vascular smooth muscle cells by TNF and PDGF: overlapping and complementary signal transduction mechanisms. Cardiovasc Res 65: 674-682, 2005.
31. Rectenwald J, Moldawer L, Huber T, Seeger J, and Ozaki C. Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation 102: 1697-1702, 2000.
32. Schaper W and Buschmann I. Arteriogenesis, the good and bad of it. Cardiovasc Res 43: 835-837, 1999.
33. Schaper W and Scholz D. Factors regulating arteriogenesis. Arterioscler Thromb Vasc Biol 23: 1143-1151, 2003.
34. Seiler C, Pohl T, Wustmann K, Hutter D, Nicolet PA, Windecker S, Eberli FR, and Meier B. Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation 104: 2012-2017, 2001.
35. Selzman CH, Shames BD, Reznikov LL, Miller SA, Meng X, Barton HA, Werman A, Harken AH, Dinarello CA, and Banerjee A. Liposomal delivery of purified inhibitory-κBα inhibits tumor necrosis factor-α-induced human vascular smooth muscle proliferation. Circ Res 84: 867-875, 1999.
36. Sugano M, Tsuchida K, and Makino N. Intramuscular gene transfer of soluble tumor necrosis factor-α receptor 1 activates vascular endothelial growth factor receptor and accelerates angiogenesis in a rat model of hindlimb ischemia. Circulation 109: 797-802, 2004.
37. Tak PP, Taylor PC, Breedveld FC, Smeets TJ, Daha MR, Kluin PM, Meinders AE, and Maini RN. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor-α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 39: 1077-1081, 1996.
38. Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R, Feldmann M, and Maini RN. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor-α blockade in patients with rheumatoid arthritis. Arthritis Rheum 43: 38-47, 2000.
39. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, and Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27: 1201-1206, 1996.
40. Van Royen N, Hoefer I, Bottinger M, Hua J, Grundmann S, Voskuil M, Bode C, Schaper W, Buschmann I, and Piek JJ. Local monocyte chemoattractant protein-1 therapy increases collateral artery formation in apolipoprotein E-deficient mice but induces systemic monocytic CD11b expression, neointimal formation, and plaque progression. Circ Res 92: 218-225, 2003.
41. Van Royen N, Hoefer I, Buschmann I, Heil M, Kostin S, Deindl E, Vogel S, Korff T, Augustin H, Bode C, Piek JJ, and Schaper W. Exogenous application of transforming growth factor-β1 stimulates arteriogenesis in the peripheral circulation. FASEB J 16: 432-434, 2002.
42. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, and Burge DJ. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340: 253-259, 1999.